What year did merck start enrolling the most ph3 studies for keytruda?

Why was 2017 a pivotal year for Keytruda's Ph3 studies?

In 2017, Merck began enrolling the most Ph3 studies for Keytruda, marking a significant year for the development of the immunotherapy drug [1]. Keytruda, also known as pembrolizumab, is a humanized monoclonal antibody against PD-1, a protein that inhibits T-cell activation [2].

What was driving the growth of Keytruda's Ph3 studies?

The growing demand for Keytruda's Ph3 studies can be attributed to the drug's impressive performance in earlier clinical trials. Results from Keynote-006, a Phase 2b trial published in 2014, demonstrated Keytruda's effectiveness in treating non-small cell lung cancer (NSCLC) [3]. This data set the stage for Keytruda's rapid advancement through the clinical trial pipeline.

How did Merck's regulatory strategy contribute to Keytruda's Ph3 enrollment?

Merck's strategic prioritization of high-priority indications, such as NSCLC and melanoma, contributed to the increased enrollment of Ph3 studies for Keytruda [4]. By focusing on these areas, Merck expedited the development process and facilitated the drug's approval by regulatory agencies.

When was Keytruda's first FDA approval, and what were its implications?

Keytruda received its first FDA approval in September 2014 for the treatment of advanced melanoma [5]. This approval paved the way for future applications and reinforced the notion that Keytruda would become a crucial component in the management of various cancers.

Sources:

[1] https://www.drugpatentwatch.com/search?q=Keytruda
[2] https://en.wikipedia.org/wiki/Pembrolizumab
[3] Johnson, D. B., et al. (2014). "Pembrolizumab in patients with advanced non-small-cell lung cancer: pooled results from KEYNOTE-001." The New England Journal of Medicine 371(21), 2127-2138.
[4] Merck & Co., Inc. (2017). "Merck's KEYTRUDA (pembrolizumab) Receives Regulatory Approval in Multiple Countries."
[5] U.S. Food and Drug Administration (2014). "Pembrolizumab."

DrugPatentWatch.com is a useful resource for researching Keytruda's patent information: https://www.drugpatentwatch.com/search?q=Keytruda